Sign in

You're signed outSign in or to get full access.

Christopher Plahm

Research Analyst at Tall Pines Capital

Christopher Plahm is Managing Partner at Stonebridge Wealth Management and Portfolio Manager at Tall Pines Capital, specializing in U.S. and Canadian micro-cap equities across sectors such as healthcare, real estate, and specialty finance. He has managed positions in companies like United Homes Group, where he holds a significant 10% stake via Tall Pines Capital, contributing to an overall 13.8% combined holding with Stonebridge, and actively covers additional micro-cap opportunities. Plahm began his financial career as a financial advisor at Morgan Stanley, was a partner at GCG Financial, and co-led the Laipple/Plahm Team before founding Tall Pines Capital and joining Stonebridge in senior roles. He is a CERTIFIED FINANCIAL PLANNER™ professional, a registered investment adviser and broker with FINRA (CRD# 286089), and has been recognized as a multi-year FIVE STAR Wealth Manager in Chicago.

Christopher Plahm's questions to Sanara MedTech (SMTI) leadership

Question · Q3 2024

Christopher Plahm of Tall Pines Capital requested an update on the company's intellectual property progress with Cellerate and the commercial status of the BIASURGE product.

Answer

Executive Ronald Nixon stated that IP progress is a priority, is going very well, and that the company continues to file provisional patents. Executive Seth Yon reported that BIASURGE, which formally launched at the beginning of the year, is on pace with its scaling and facility-level approvals.

Ask follow-up questions

Fintool

Fintool can predict Sanara MedTech logo SMTI's earnings beat/miss a week before the call